Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.
Illumina Inc (NASDAQ: ILMN) is described by the company as a global leader in DNA sequencing and array-based technologies, serving research, clinical, and applied markets across genomics, multiomics, and proteomics. This news page aggregates recent press releases and announcements so readers can follow how Illumina’s technologies, collaborations, and financial disclosures evolve over time.
Company news highlights include product and platform launches, such as Illumina Connected Multiomics, a cloud-based software platform for analyzing and visualizing multiomic data, and Illumina Protein Prep, which the company states delivers broad coverage of the blood proteome and supports large-scale genomics studies. Illumina has also announced the Illumina Billion Cell Atlas, a large genome-wide genetic perturbation dataset developed through its BioInsight business to support AI-driven drug discovery in collaboration with pharmaceutical partners.
Investors can use this news feed to track Illumina’s preliminary financial results, earnings announcements, and capital markets activities, as reflected in press releases tied to quarterly and annual results and conference presentations. The page also captures updates on strategic agreements and acquisitions, including Illumina’s planned acquisition of Standard BioTools’ aptamer-based and functional proteomics business, as described in SEC filings and related communications.
In addition, Illumina’s news often covers leadership appointments, regulatory and market developments, and collaborations with genomics and population health partners such as MyOme. By reviewing these updates in one place, readers can better understand how Illumina positions its sequencing, multiomic, and proteomic offerings and how its corporate strategy and partnerships may influence its role in genomics and precision medicine. Bookmark this page to review new company-issued information as it becomes available.
Point32Health, parent of Harvard Pilgrim Health Care, expands a pilot offering GRAIL's Galleri multi-cancer detection test to Maine members at no cost. This initiative aims to gather real-world evidence on healthcare utilization and patient outcomes, targeting high cancer rates in Maine. The Galleri test can detect signals across over 50 cancer types with a low false positive rate. Point32Health stands out as the first U.S. commercial health plan to integrate Galleri, complementing existing cancer screenings to enhance early detection.
Summary not available.
GRAIL, LLC announced findings from its CCGA study, revealing that methylation techniques demonstrated the highest cancer signal detection sensitivity at 98% specificity, outperforming other approaches. This research supports the development of the Galleri® multi-cancer early detection blood test, capable of identifying signals from over 50 cancer types. The study involved 2,800 participants and emphasized the importance of rigorous genomic measures for cancer detection. The findings will refine the Galleri test, enhancing its capability in early cancer diagnosis.
Illumina, Inc. (NASDAQ: ILMN) will present at two upcoming investor conferences. The Evercore ISI HealthCONx Conference is on November 29, 2022, featuring a fireside chat at 8:20am PT. Additionally, Illumina will participate in the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, starting at 6:00am PT. Webcasts will be accessible through Illumina’s Investor Info website, with replays available for 30 days after each event.
Illumina reported Q3 2022 revenue of $1.12 billion, a 1% increase year-over-year. The company incurred a GAAP diluted loss per share of $(24.26), driven by a $3.91 billion goodwill impairment related to the GRAIL segment. Non-GAAP diluted EPS stood at $0.34, down from $1.45 in Q3 2021. For fiscal 2022, the company expects overall revenue growth to be flat to 1% higher and anticipates a GAAP diluted loss per share between $(26.56) and $(26.41). Innovation continues with 50 orders for the new NovaSeq X.
Anavasi Diagnostics, a medical technology firm, has elected three new board members: Bryan Crane, PhD, from Illumina, Arthur Kirsch from Liquidia Corp, and David Vied from Cyanotech Corporation. This expansion aims to leverage their extensive industry experience to enhance Anavasi's growth as it progresses through clinical trials and product development. Nelson Patterson, CEO, expressed optimism about the fresh perspectives these members will bring. Anavasi has secured $6 million in seed funding and is currently in a $20 million Series A fundraising round.
Twist Bioscience Corporation (NASDAQ: TWST) and Illumina, Inc. (NASDAQ: ILMN) announced a partnership to enhance research capabilities with the co-branded Twist® for Illumina® Exome 2.0 Plus panel. Twist will manufacture the panel, which features high uniformity, low off-target rates, and is designed for Illumina sequencers. This collaboration aims to provide a market-leading exome panel, facilitating improved customer access to advanced genomic solutions. Both companies are recognized as leaders in genomics and next-generation sequencing.
Illumina (NASDAQ: ILMN) launched the Urinary Pathogen Infectious Disease/Antimicrobial Resistance (ID/AMR) Panel (UPIP) on Nov. 1, 2022, utilizing precision metagenomics to identify over 170 pathogens and 3700 AMR markers within 48 hours. This panel addresses urgent public health needs, as urinary tract infections (UTIs) lead to 10 million office visits and 1 million hospitalizations annually in the U.S. UPIP enhances infection detection without traditional culture methods, positioning Illumina as a leader in combating antimicrobial resistance and supporting global health preparedness.
Illumina and GenoScreen have formed a partnership aimed at combating multidrug-resistant tuberculosis (MDR-TB) globally. This collaboration will enhance the detection capabilities of countries heavily affected by TB, aligning with the World Health Organization's goal to eliminate the disease by 2035. The partnership involves the integration of Illumina's sequencing products with GenoScreen's Deeplex Myc-TB assay, allowing for rapid identification of anti-TB drug resistance. Currently, less than half of MDR-TB cases are detected, highlighting the critical need for improved testing methods.
Summary not available.